Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E21.04 EPS (ttm)2.57 Insider Own0.10% Shs Outstand1.59B Perf Week1.05%
Market Cap86.10B Forward P/E14.24 EPS next Y3.80 Insider Trans35.60% Shs Float1.57B Perf Month1.67%
Income4.14B PEG2.39 EPS next Q0.76 Inst Own79.50% Short Float0.88% Perf Quarter10.48%
Sales19.02B P/S4.53 EPS this Y-23.10% Inst Trans13.65% Short Ratio1.76 Perf Half Y12.50%
Book/sh2.94 P/B18.39 EPS next Y20.69% ROA14.50% Target Price64.43 Perf Year28.12%
Cash/sh5.72 P/C9.46 EPS next 5Y8.80% ROE101.40% 52W Range40.86 - 57.83 Perf YTD4.93%
Dividend1.68 P/FCF33.06 EPS past 5Y0.00% ROI23.20% 52W High-6.48% Beta-
Dividend %3.11% Quick Ratio2.60 Sales past 5Y- Gross Margin76.30% 52W Low32.35% ATR1.23
Employees25000 Current Ratio2.80 Sales Q/Q5.40% Oper. Margin31.70% RSI (14)46.88 Volatility1.73% 2.30%
OptionableYes Debt/Eq3.07 EPS Q/Q1.70% Profit Margin21.80% Rel Volume1.44 Prev Close54.48
ShortableYes LT Debt/Eq3.06 EarningsJul 23 Payout61.50% Avg Volume7.90M Price54.08
Recom1.80 SMA20-2.12% SMA50-0.20% SMA2007.34% Volume11,408,907 Change-0.73%
24-Jun-14Reiterated Argus Buy $59 → $65
06-Jan-14Reiterated UBS Neutral $46 → $56
29-Oct-13Reiterated Argus Buy $52 → $59
12-Aug-13Initiated Argus Buy $52
15-May-13Reiterated R. F. Lafferty Buy $47.90 → $61
29-Apr-13Reiterated Barclays Equal Weight $41 → $44
15-Apr-13Reiterated Barclays Equal Weight $37 → $41
24-Jul-14 03:50PM  Pharma, Biotech M&As Heat Up: Tax Inversion in Focus Zacks
02:07PM  [$$] AbbVie's Plans Hinge on Humira at The Wall Street Journal
01:58PM  Will AbbVie (ABBV) Surprise This Earnings Season? Zacks
12:56PM  Perrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0% at theflyonthewall.com
07:52AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen Zacks
06:54AM  GlaxoSmithKline Slumps: GSK Falls 5.9% in Session Zacks
06:00AM  Obama presses to close corporate tax loophole 'inversions' Reuters
23-Jul-14 03:43PM  Biogen Idec Beats And Raises: Reassessing Its Prospects at Seeking Alpha
02:44PM  Surprise: The Real Costs Of Inversions Are Paid By Ordinary Shareholders at Seeking Alpha
01:16PM  Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 Zacks
12:44PM  AbbVie to Host Second-Quarter Earnings Conference Call PR Newswire
10:36AM  Durbin Harshly Criticizes Walgreen for Tax Inversion Plans at The Wall Street Journal
09:41AM  [video] Faber Report: Inversion train rolling at CNBC
09:35AM  Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth Zacks
08:44AM  Shire to spend about $225M on drug collaboration AP
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Virus at Bloomberg
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Hepatitis C Virus? Bloomberg
22-Jul-14 05:30PM  Dividend Growth Investing: An Open Portfolio For Your Review at Seeking Alpha
03:30PM  Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts Zacks
02:38PM  [video] Don't Expect Tax Inversion Fever to Break Anytime Soon at TheStreet
02:04PM  Senate Panel Takes On Tax Inversions at New York Times
11:41AM  Top U.S. lawmaker wants corporate tax loophole 'plugged now' Reuters
10:52AM  No Need To Envy Tax-Inversion Takeovers: Better Tax Deal Awaits at Forbes
10:01AM  Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal Zacks
09:32AM  Here's What You Need to Know About AbbVie and GlaxoSmithKline's Upcoming Earnings at Motley Fool
21-Jul-14 07:05PM  U.S. Senate panel to debate wave of corporate tax-avoidance deals Reuters
03:58PM  Abbvie's $8 billion in tax breaks from Shire deal may come just in time at MarketWatch
02:10PM  Welcome to Ireland, AbbVie at Motley Fool
02:06PM  AbbVie Set to Acquire UK-Based Shire in Q4 Zacks
01:03PM  ABBV, MRK And PFE, Pushing Health Care Sector Downward at TheStreet
11:34AM  Tax inversions allow firms to avoid state taxes at USA TODAY
11:00AM  [video] Mega drug merger at CNBC
10:41AM  Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers at The Wall Street Journal
10:22AM  Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers at The Wall Street Journal
09:33AM  AbbVie Gets Its 'Tax Break' In Shire at Seeking Alpha
08:01AM  AbbVie acquisition positive, says Argus at theflyonthewall.com
04:30AM  Why AbbVie Inc Is Buying Shire PLC at Motley Fool
12:00AM  Sullivan & Cromwell Advises AbbVie on Deal: Business of Law at Bloomberg
20-Jul-14 12:21PM  Takeover deals highlight bets on equities outperforming bonds at Financial Times
01:29AM  S&P 500 And Dividend Aristocrat Dogs Mark 2.5% To 20% July Upsides at Seeking Alpha
19-Jul-14 01:06PM  3 Dividend Value Stocks to Boost Your Income at Motley Fool
08:00AM  Can Anything Stop Drug Companies From Fleeing The U.S. Tax System? at Forbes
07:05AM  The AbbVie, Shire Tax Inversion Will Actually Increase US Tax Revenues at Forbes
12:00AM  AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal at Bloomberg
18-Jul-14 11:09PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
11:08PM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
10:39PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
10:39PM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
09:49PM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
09:49PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
09:29PM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
08:47PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
08:01PM  [video] The $55B Deal That Jack Lew Probably Doesn't Like at Bloomberg
07:12PM  With Shire, Did AbbVie Count Its Chickens Before They Hatched? at Motley Fool
06:34PM  AbbVie Flees U.S. Tax Burden With $54B Shire Deal at Wall St. Cheat Sheet
06:04PM  AbbVie purchase of Shire worth the premium, Barron's reports at theflyonthewall.com
05:19PM  Stocks recover from Thursday's decline and refocus on earnings Hot Stock Minute
05:16PM  [video] Pharma inversion deals at CNBC
05:11PM  AbbVie: Shire Buy More Than Just Taxes Investor's Business Daily
05:08PM  U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal Reuters
05:02PM  AbbVie Inc. Wins the Shire at Motley Fool
04:32PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
04:01PM  [$$] AbbVie's $55 Billion Deal To Buy Shire Is Worth It at Barrons.com
04:00PM  NASDAQ SURGES, DOW ADDS 120: Here's What You Need To Know Business Insider
04:00PM  NASDAQ SURGES, DOW ADDS 120: Here's What You Need To Know Business Insider
03:58PM  [video]Could AbbVie's Buyout of Shire Make It a New Dividend Aristocrat? at TheStreet
03:53PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
03:14PM  Stock Market Today: Markets Shrug Off Escalating Geopolitical Conflict at TheStreet
03:09PM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
03:09PM  AbbVie and Shire tie the knot but investors seem wary of regulators at MarketWatch
02:58PM  [video] AbbVie Finally Clinches Shire Takeover Deal Valued at $55 Billion at TheStreet
02:49PM  Stocks Are Rallying Into The Weekend Business Insider
02:23PM  [audio] Newscast: Market gains, Sotheby's shrinks at MarketWatch
02:07PM  [$$] AbbVie's $55 Billion Deal To Buy Shire Is Worth It at Barrons.com
02:00PM  AbbVie Inc. -- Moody's affirms AbbVie at Baa1/P-2; revises outlook to stable at Moody's
01:23PM  Will Congress Scuttle the AbbVie-Shire Merger? at Fox Business
01:01PM  Shire demands assurances in backroom fight over tax inversion at Financial Times
12:52PM  AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal Bloomberg
12:46PM  AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal Bloomberg
12:45PM  [audio] Newscast: Stocks regain some ground after selloff at MarketWatch
12:27PM  U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal Reuters
12:01PM  AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal Bloomberg
11:58AM  Glance: Biggest corporate deals so far this year AP
11:43AM  AbbVie to buy Shire in $55-billion deal that slashes tax rate at Los Angeles Times
11:42AM  AbbVie, Shire agree on $55B combination AP
11:38AM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
11:36AM  AbbVie and Shire tie the knot but investors seem wary of regulators at MarketWatch
11:32AM  AbbVie Seals $54 Bil Shire Deal, Sharp Tax Rate Cut at Investor's Business Daily
11:29AM  [$$] Taxing Terms in AbbVie's Shire Deal at The Wall Street Journal
11:03AM  AbbVie Buys Shire For $54 Billion at Investor's Business Daily
10:57AM  AbbVies Shire merger backed with 13.5 billion pound bridge loan Reuters
10:37AM  Shire Agrees to AbbVie $55B Takeover Offer at TheStreet
10:34AM  Shire downgraded to Neutral from Overweight at Piper Jaffray at theflyonthewall.com
10:24AM  [$$] AbbVie to Buy Shire for $54 Billion at The Wall Street Journal
09:55AM  AbbVie Seals $54.8 Billion Shire Deal in Booming Tax Migration From U.S. Bloomberg
09:55AM  AbbVie to Buy Shire for $54.8 billion in biggest inversion at Los Angeles Times
09:54AM  [video] U.S. Markets Open Higher, General Electric Q2 Meets Forecasts at TheStreet
09:54AM  [video] The Top Ten Stocks for Friday, July 18 at Bloomberg
09:51AM  AbbVie CEO says tax is not primary reason for buying Shire Reuters
09:29AM  AbbVie and Shire seal $55B, tax-slashing deal at USA TODAY
AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOMar 04Sale51.204,799245,706395,403Mar 04 05:13 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 03Sale50.034,143207,284273,585Mar 04 05:18 PM
SALEKI-GERHARDT AZITASVP, OperationsMar 03Sale50.252,443122,76085,828Mar 04 05:17 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 03Sale50.223,948198,259180,068Mar 04 05:12 PM
ALBAN CARLOSEVP, Commercial OperationsMar 03Sale50.092,882144,356205,138Mar 04 05:10 PM
HURWICH THOMAS A.VP, ControllerFeb 18Option Exercise44.939,138410,57061,016Feb 19 05:33 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCFeb 18Option Exercise43.218,928385,779256,224Feb 19 05:35 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 18Sale51.2346523,82283,913Feb 19 05:35 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 10Option Exercise45.061,46666,05865,856Feb 12 04:49 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Sale47.8468732,86664,390Feb 07 05:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 05Sale47.781,46069,76385,470Feb 07 05:08 PM